Sinus Infection

Sinus Infection (Rhinosinusitis): A Nutrition and Natural-Health Reference

1. Definition and Overview

Sinusitis is an inflammation of the membranes lining the air-filled spaces around the nose — the paranasal sinuses — and the nose itself, and is also known as "rhinosinusitis." The term "sinusitis" refers specifically to inflammation of the mucosa of the paranasal sinuses, regardless of the cause. As understanding of the pathophysiology of the nasal mucosa has evolved, the differentiation between rhinitis and sinusitis has become less apparent.

The sinuses are part of the upper airways and are connected to the nasal cavity. They are made up of several spaces in the skull found from the forehead down to the teeth of the upper jaw, and are known as the frontal sinuses, the sphenoid sinus, the ethmoid sinus, and the maxillary sinuses. These sinuses are lined with a layer of soft tissue bearing tiny hairs (ciliated epithelium), known as the mucous membrane, which produces a fluid that drips down through the nose and throat.

Acute rhinosinusitis is a frequently diagnosed condition, accounting for approximately 30 million primary care visits annually and contributing to an estimated $11 billion in healthcare costs.

2. Classification and Clinical Presentation

Sinusitis can be acute (short-term) or chronic (lasting for an extended period), and it can be categorized as infectious or non-infectious. Acute sinusitis often follows a viral upper respiratory infection or allergic reaction and typically resolves within a few weeks, while chronic sinusitis is characterized by persistent inflammation and symptoms lasting for at least 12 weeks.

Patients with chronic rhinosinusitis experience at least two or more of the following symptoms for at least 12 weeks: blocked nose, discharge from their nose or runny nose, pain or pressure in their face, and/or a reduced sense of smell (hyposmia). Some people will also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the nasal passage and sinuses.

Frequent clinical manifestations of acute rhinosinusitis include persistent symptoms with nasal discharge or cough or both, presentation with fever accompanying purulent nasal discharge, and worsening symptoms.

Recurrent sinusitis is defined as four or more episodes lasting less than four weeks with complete symptom resolution between episodes. Classification of rhinosinusitis is based more on clinical consensus rather than exclusively on empirical research.

3. Body Systems Involved

The pathophysiology of sinusitis is based on three main principles: obstruction of sinus drainage, mucosal swelling and inflammation, and altered mucociliary transport through the coordinated activity of the ciliated columnar epithelium. Hypoxia resulting from sinus obstruction may disrupt ciliary function.

The pathophysiology of sinusitis involves a complex interplay of factors that result in inflammation and, sometimes, infection of the paranasal sinuses. The paranasal sinuses are air-filled cavities located in the bones of the face and skull, and they are lined with mucous membranes.

The immune system is centrally involved. While the cause and pathogenesis of acute rhinosinusitis are typically associated with infection, chronic rhinosinusitis results from complex inflammatory processes and is generally a consequence of a vicious interaction between the host immune system and the microbiome at the nasal and sinus mucosal surfaces. The immune barrier hypothesis is the main accepted host-driven theory to clarify the pathogenesis of CRS, with local defects in the mechanical and innate immune barriers increasing the formation of microbial colonies and subsequent immune responses.

The respiratory tract and the mucociliary clearance apparatus are directly implicated. Untreated or severe sinusitis can lead to complications such as the spread of infection to nearby structures, including the eyes, brain, or bone, though these complications are rare. Sinusitis may extend to the central nervous system, where it may cause cavernous sinus thrombosis, retrograde meningitis, and epidural or brain abscess.

4. Microbial Causes

Acute rhinosinusitis is most commonly caused by viruses and is self-limiting in nature; however, symptoms may persist beyond 10 days when secondary bacterial infection prevails.

Most acute sinusitis is generally of viral origin — for example, rhinoviruses, coronaviruses, and influenza viruses. Bacterial pathogens include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Fungal sinusitis is particularly challenging to treat and most often affects individuals with compromised immune systems or those exposed to certain environmental fungi.

5. Contributing and Associated Factors

5.1 Structural and Anatomical Factors

The potential contributing factors underlying chronic sinusitis include anatomical anomalies of the sinonasal complex, structural nasal abnormalities, inherited mucociliary dysfunction, cystic fibrosis, and Young's syndrome. Among the most common risk factors are nasal allergies, nasal blockage, and deviation of the nasal septum.

5.2 Immunological and Systemic Disease Factors

Recent findings demonstrate that genetics, comorbid medical conditions including airway diseases, gastroesophageal reflux disease, inflammatory and autoimmune diseases, and various demographic and environmental factors are associated with having a chronic rhinosinusitis (CRS) diagnosis.

Specific monogenic disorders including cystic fibrosis, primary immunodeficiencies, and primary ciliary dyskinesia (Kartagener's syndrome) are associated with a high prevalence of CRS.

Risk factors for extensive sinus disease include age greater than 50 years, a history consistent with asthma, the presence of atopy, an IgG4 level ≥40 mg/dL, and a peripheral eosinophil count ≥200/μL.

5.3 Environmental and Occupational Factors

Chronic rhinosinusitis has a likely multifactorial etiology potentially including hazardous occupational and environmental exposures. The current state of the literature allows very few firm conclusions about the role of hazardous occupational or environmental exposures in CRS, leaving a critical knowledge gap regarding potentially modifiable risk factors for disease onset and progression.

Smoke exposure is a recognized environmental risk factor, and there is a significant correlation between CRS and body mass index, with increased prevalence in overweight and obese individuals compared with normal-weight individuals.

6. Nutrients, Herbs, and Natural Ingredients

6.1 Vitamin C

Traditional Use

Vitamin C (ascorbic acid) has been employed since at least the mid-20th century as a general immune-supportive agent across European and North American folk and naturopathic traditions, administered orally in high doses at the onset of upper respiratory symptoms. Its use in this context predates formal clinical investigation.

Scientific Evidence

The objective of systematic inquiry in this area has been to assess the effectiveness of oral vitamin C supplements to prevent and treat acute upper respiratory tract infections (URTIs) in adults and children. URTIs comprise a number of infections involving the nose, sinuses, pharynx, or larynx, and most are caused by viruses, although bacteria and rarely fungi can also be involved.

A Cochrane review identified 31 comparisons examining the effect of regular vitamin C supplementation of at least 0.2 g/day on 9,745 episodes of respiratory virus infection. In adults the duration of colds was reduced by 7.7% (95% CI 3.7% to 11.8%, p = 0.00018) and in children by 14.2% (95% CI 7.3% to 21.1%, p = 0.000053). These findings indicate that vitamin C has physiological effects, though the review did not demonstrate treatment effects on viral infections that had already started.

The latest meta-analysis on vitamin C's effect on common cold found that regular vitamin C supplementation in adults helped decrease cold duration by 8% (3–12%) and reduced cold severity during episodes.

Evidence strength: Moderate evidence for modest reduction in duration of viral upper respiratory infections (which commonly precede or accompany sinusitis) from regular supplementation; evidence for treatment of established infections is weak. No large clinical trials are specific to sinusitis.

6.2 Vitamin D

Traditional Use

Vitamin D was not traditionally used for respiratory infections in the same way as herbal remedies; its investigation in sinusitis is primarily a product of modern nutritional immunology research from the late 20th and early 21st centuries.

Scientific Evidence

Extensive evidence from research suggests that vitamin D3 functions locally inside the respiratory epithelium as an immunomodulator of innate and adaptive immunity. Vitamin D3 appears to play a role in the control of the immune system by triggering innate antibacterial responses while typically having a tolerogenic effect on adaptive immunity.

Sinonasal epithelial cells reportedly express 1-hydroxylase and have the ability to locally generate 1,25-vitamin D3, suggesting a local, autocrine immunological role within the sinus tissue itself.

Chronic rhinosinusitis is marked by inflammation of the paranasal sinuses and mucosal lining of the nose, and can be classified as CRS with nasal polyps or CRS without polyps. In recent years there has been increased attention on the immunological role of vitamin D in treating CRS, coupled with the observation of vitamin D deficiency among CRS patients.

Vitamin D3 is a steroid hormone with known anti-proliferative properties. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have been shown to be VD3 deficient, and VD3 deficiency is associated with worse disease in patients with CRSwNP.

Recent evidence has indicated a relationship between serum 25-hydroxyl vitamin D deficiency and CRS. Vitamin D has a role in immune responses, including induction of cathelicidins — a group of antimicrobial peptides produced by neutrophils, macrophages, and epithelial cells. Several studies have also reported an inverse relationship between serum 25-OH-VitD levels and incidence of upper respiratory tract infection.

Regarding supplementation specifically, vitamin D's ability to augment innate and adaptive immune responses has sparked interest in its immunologic role in the treatment of CRS. However, evidence from trials of supplementation is mixed: in a large-scale randomized controlled trial (the VITAL trial, n >15,000), supplemental vitamin D3 at 2,000 IU/day did not lower upper respiratory infection risk overall in older adults not selected for vitamin D deficiency, although the intervention appeared safe.

Evidence strength: Observational studies consistently show an association between vitamin D deficiency and greater CRS severity. The mechanistic rationale is well-supported. Interventional evidence remains mixed; supplementation appears most likely to benefit those who are actually deficient.

6.3 Zinc

Traditional Use

Zinc has been used in various forms for wound healing and immune support across numerous medical traditions. The use of zinc lozenges and nasal preparations specifically for upper respiratory infections is primarily a modern phenomenon originating in North American and European naturopathic practice from the 1980s onward.

Scientific Evidence

The common cold is characterized by acute inflammation of the nose, sinuses, pharynx, and larynx, mainly due to viral infection. Multiple systematic reviews have examined zinc's impact on acute respiratory infections. Zinc supplementation did not significantly reduce the risk of acute respiratory infections but shortened the duration of symptoms substantially (percent difference: −47%; 95% CI −73% to −21%; p=0.0004).

Evidence strength: Reasonably strong evidence (multiple RCTs, systematic reviews) that zinc supplementation can shorten the duration of viral upper respiratory symptoms, which are the most common precursor to sinusitis. Direct evidence for sinusitis-specific outcomes is limited.

6.4 Bromelain

Traditional Use

Bromelain is a proteolytic enzyme complex extracted from the stems of pineapple (Ananas comosus). It has been used in Central and South American folk medicine from pineapple plant extracts as an anti-inflammatory and digestive aid. Its formalized use in European phytomedicine for respiratory and ENT conditions developed in the mid-to-late 20th century.

Scientific Evidence

Bromelain has been proposed as an alternative treatment for sinusitis and is licensed as a therapeutic agent for sinus and nasal swelling and inflammation following operations on the nose, ear, and throat by the German Commission E.

Bromelain could be an important mucolytic agent for allergic rhinitis, rhinosinusitis, and severe rhinosinusitis by decreasing proinflammatory prostaglandin production and reducing swelling in nasal routes. Bromelain also significantly reduces mucus production and improves drainage, and elicits an anti-inflammatory response by reducing prostaglandin E2 (PGE-2) and cyclooxygenase-2 (COX-2) synthesis.

In human trials: The activity of bromelain in the treatment of acute sinusitis was assessed in a multicentric, epidemiological cohort study including 116 children. The mean duration of symptoms was 6.66 days in subjects treated with bromelain extract alone, 9.06 days in children receiving a combination of bromelain and standard therapy, and 7.95 days in children treated with standard therapy alone. Patients in the monotherapy bromelain group had significantly faster symptom recovery (p = 0.005) compared to the other treatment groups.

For chronic rhinosinusitis, a pilot study published in the journal B-ENT (2013) reported: preliminary results indicate good tolerability, symptom control, and improvement in quality of life for the treatment of CRS using bromelain tablets (500 FIP).

Administration of bromelain among children suffering from acute sinusitis shortened the duration of symptoms and accelerated recovery when compared with usual care regimens. Combined bromelain and antibiotic therapy was shown to be more effective than antibiotics alone in sinusitis, among other conditions.

An analysis of three minor, but well-designed trials showed that bromelain helps to alleviate symptoms of sinus infections.

Evidence strength: Preliminary-to-moderate. The German Commission E regulatory approval provides an official endorsement for ENT use. The available human trial data are encouraging but mostly small, and lack of large, high-quality RCTs specific to sinusitis limits firm conclusions.

6.5 N-Acetylcysteine (NAC)

Traditional Use

NAC is a pharmaceutical-grade derivative of the amino acid L-cysteine. It has no traditional herbal or folk medicine history; its use originated from clinical pharmacology in the 1960s as a mucolytic agent for conditions such as chronic bronchitis. Its application to sinusitis developed later as an extension of its established bronchopulmonary mucolytic role.

Scientific Evidence

NAC acts primarily as a mucolytic via a clear biochemical mechanism: in a study of 32 sinusitis patients treated with a NAC solution administered by sinus irrigations, the authors concluded that NAC is an effective mucolytic agent.

In a prospective single-blind randomized controlled trial of post-surgical CRS patients, the study assessed the effectiveness of NAC irrigation during the post-endoscopic sinus surgery (ESS) period in patients with CRS without nasal polyposis. Forty-nine patients were assigned to receive either NAC or saline irrigations twice daily for one month. The NAC group showed significant improvement in VAS scores for postnasal drip, smell dysfunction, and crust 2 weeks after the operation. NAC irrigation showed benefits over saline irrigation in terms of improving postnasal drip, smell dysfunction, and crust after ESS for CRS without nasal polyposis in the immediate postoperative period.

In the context of polypous rhinosinusitis, a study of 98 patients using NAC orally at 600 mg for 6 months post-surgery found: long-term use of NAC in polypous rhinosinusitis increases the effectiveness of surgical treatment, reduces the frequency of relapses, and also improves the general condition of patients.

However, the overall evidence base for NAC in sinusitis remains limited: a more recently published phase 3 study in recurrent acute sinusitis did not meet the expectations for a recommendation of mucolytics in the current treatment guidelines for rhinosinusitis. To the best of investigators' knowledge, rigorous investigation of NAC for rhinosinusitis according to current regulatory requirements has been limited.

Evidence strength: Weak-to-preliminary for standalone sinusitis treatment. The mucolytic mechanism is well-established; human trial data for sinusitis specifically are small, of variable design quality, and have shown inconsistent results. More rigorous RCTs are needed.

6.6 Pelargonium sidoides (Umckaloabo)

Traditional Use

The importance of Pelargonium species, most notably Pelargonium reniforme and Pelargonium sidoides, in traditional medicine in the southern African region is well documented. The plant has been used by indigenous southern African peoples for generations as a treatment for respiratory ailments and gastrointestinal conditions, and was introduced to European phytomedicine in the early 20th century under the name "Umckaloabo."

Scientific Evidence

Clinical trials have shown that a modern aqueous-ethanolic formulation of P. sidoides extracts (EPs® 7630) is an efficacious treatment for disorders of the respiratory tract, including bronchitis and sinusitis. In order to provide a rationale for its therapeutic activity, extracts have been evaluated for antibacterial activity and their effects on non-specific immune functions. Only moderate direct antibacterial capabilities against a spectrum of bacteria have been noted. In contrast, a large body of in vitro studies has provided convincing evidence for an anti-infective principle associated with activation of the non-specific immune system, and significant inhibition of interaction between bacteria and host cells — a key to the pathogenesis of respiratory tract infections — has emerged from recent studies.

The most clinically relevant evidence comes from a double-blind, placebo-controlled trial: a randomized, double-blind, multicenter trial enrolled 103 patients with radiographically and clinically confirmed acute rhinosinusitis and compared EPs 7630 with placebo. EPs 7630 was found to have superior efficacy and tolerance, based on changes in sinusitis severity scores.

The Cochrane Collaboration assessed this body of evidence: one study was available specifically for the treatment of acute sinusitis in adults. It showed that the drug was effective in resolving all symptoms including headaches and nasal discharge when taken for an extended time period. Adverse events were more common with P. sidoides, but none were severe. Overall, the quality of the evidence was considered low or very low for all major outcomes, as there were few studies per disease entity and all were from the same investigator (the manufacturer) and performed in the same region (Ukraine and Russia).

P. sidoides may be effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults, but doubt exists. It may be effective in relieving symptoms in acute bronchitis in adults and children, and sinusitis in adults. The overall quality of the evidence was considered low for main outcomes in acute bronchitis in children and adults, and very low for acute sinusitis and the common cold.

Evidence strength: Low per Cochrane assessment. There is one positive RCT for acute sinusitis, but significant limitations around investigator independence and geographic concentration of trials constrain confidence. Mechanistic plausibility is supported by in vitro data.

6.7 Quercetin

Traditional Use

Quercetin is a flavonoid found naturally in onions, apples, capers, and other plant foods. Its use as a discrete supplement is modern; foods rich in quercetin have been used in various European and Asian food-medicine traditions as general anti-inflammatory agents and as remedies for respiratory congestion, but the application of isolated quercetin to sinusitis is a product of contemporary nutritional medicine.

Scientific Evidence

Clinical trials of quercetin for respiratory infections have been included in network meta-analyses alongside other micronutrients; 4 quercetin trials were among 107 RCTs with 101,751 participants in one major systematic review on nutritional supplements and respiratory tract infection.

Regarding mechanism, quercetin's proposed relevance to sinusitis relates primarily to its effects on allergic and inflammatory pathways. Quercetin is a flavonoid found in onions, apples, and capers, and it stabilizes mast cells and reduces histamine release — the same mechanism that drives allergic rhinitis. These in vitro and animal-model-derived mechanisms are plausible given the role of allergic inflammation in a proportion of CRS cases, but large-scale direct clinical evidence specifically for sinusitis outcomes is lacking. Evidence remains largely preliminary for sinusitis-specific endpoints.

Evidence strength: Weak for sinusitis specifically. Mechanistic rationale (mast cell stabilization, anti-inflammatory effects) is plausible and supported by in vitro data. Direct human clinical trial data targeting sinusitis outcomes are sparse and insufficiently powered.

7. Lifestyle and Dietary Factors

7.1 Nasal Saline Irrigation

Nasal irrigation (also known as nasal douche, wash, or lavage) is a procedure that rinses the nasal cavity with isotonic or hypertonic saline solutions, in which the patient instils saline into one nostril and allows it to drain out of the other nostril, bathing the nasal cavity.

The Cochrane systematic review on saline irrigation for chronic rhinosinusitis concluded: there was no benefit of a low-volume (5 mL) nebulised saline spray over intranasal steroids, but there may be some benefit of daily, large-volume (150 mL) saline irrigation with a hypertonic solution compared with placebo, although the quality of the evidence was low for three months and very low for six months of treatment.

While there is no evidence that saline is a replacement for standard therapies, the addition of topical nasal saline is likely to improve symptom control in patients with persistent sino-nasal disease.

The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 suggests that saline irrigation might be a suitable option to relieve acute respiratory tract infection symptoms, but acknowledges that the evidence is poor. A Cochrane review of saline irrigation for chronic sinusitis concluded that there may be some benefit from daily, large-volume saline irrigation with a hypertonic solution compared with placebo.

Evidence strength: Low-quality evidence overall, but the intervention is consistently identified as safe, low-cost, and likely to offer some symptom benefit. Large-volume hypertonic irrigation appears preferable to low-volume spray preparations for chronic sinusitis.

7.2 Smoking and Air Pollution

Smoking and passive smoking are recognized risk factors, increasing the chances of contracting sinusitis. Environmental factors such as smoking may increase disease risk in chronic rhinosinusitis with nasal polyps.

7.3 Body Weight and Obesity

There is a significant correlation between CRS and BMI, with increased prevalence in overweight and obese individuals compared with normal-weight individuals. The mechanisms are not fully elucidated in the current literature, but likely include obesity-associated low-grade systemic inflammation and altered immune function.

7.4 Gastroesophageal Reflux Disease (GERD)

Gastroesophageal reflux disease is among the comorbid conditions associated with a CRS diagnosis. The proposed mechanism involves reflux-induced damage to the sinonasal mucosa and microaspiration of gastric contents, though this relationship is an area of ongoing research.

7.5 Hydration and Mucociliary Function

Adequate hydration is widely discussed in authoritative ENT and nutrition literature as a factor relevant to mucociliary clearance and the viscosity of sinus secretions. Altered mucociliary transport through the coordinated activity of ciliated columnar epithelium is one of the three core pathophysiological mechanisms in sinusitis, and hypoxia resulting from sinus obstruction may further disrupt ciliary function. Maintaining adequate mucociliary transport through hydration is mechanistically plausible but has not been isolated as an independent variable in clinical trials.

7.6 Allergy Management and Diet

Multiple risk factors have been implicated in the pathogenesis of CRS, including nasal allergies and bronchial asthma. For individuals in whom allergy is a driving factor, dietary approaches that reduce systemic inflammation may be relevant; however, direct evidence linking specific dietary patterns (e.g., anti-inflammatory diets, elimination diets) to sinusitis outcomes is not well-established in the current peer-reviewed literature.

8. Summary of Evidence Strength by Agent

• Vitamin C: Moderate evidence for modest shortening of viral upper respiratory infection duration with regular supplementation; no sinusitis-specific RCTs of sufficient scale.
• Vitamin D: Consistent observational evidence linking deficiency to CRS severity; mixed interventional evidence; most benefit likely in those who are deficient.
• Zinc: Reasonably strong evidence for shortening duration of viral upper respiratory tract symptoms; limited sinusitis-specific data.
• Bromelain: Preliminary-to-moderate human trial data; German Commission E approval for ENT/sinus use; trials are small and methodologically limited.
• NAC: Biologically plausible mucolytic mechanism; small human trials showing mixed benefits; no high-quality large RCT yet completed for rhinosinusitis specifically.
• Pelargonium sidoides: One positive RCT for acute sinusitis; Cochrane-rated low-quality evidence overall; promising but requiring independent replication.
• Quercetin: Predominantly in vitro and mechanistic rationale; direct sinusitis clinical trial data are sparse; evidence is weak and preliminary for sinusitis endpoints.
• Saline nasal irrigation: Low-quality but consistent evidence of symptom benefit; considered safe and adjunctive; large-volume hypertonic irrigation preferred for CRS.

References

• Battisti AS, Modi P, Pangia J. Sinusitis. StatPearls. NCBI Bookshelf (NIH), updated 2025.
• InformedHealth.org — Overview: Sinusitis. NCBI Bookshelf (NIH/IQWiG), updated 2024.
• Anand VK. Acute rhinosinusitis in adults: an update on current management. PMC/NIH, 2008.
• Psaltis AJ, Wormald PJ. Risk factors for chronic rhinosinusitis. PMC/NIH, 2015.
• Psaltis AJ, Wormald PJ. Risk factors for chronic rhinosinusitis. PubMed abstract, 2015.
• Development and validation of a clinical risk prediction model for chronic sinusitis with nasal polyps. PMC/NIH, 2025.
• Alotaibi et al. Body Mass Index and Related Risk Factors of Sinusitis Among Adults in Saudi Arabia. Cureus, PMC/NIH, 2023.
• Thamboo A et al. Occupational and environmental risk factors for chronic rhinosinusitis: a systematic review. PMC/NIH, 2015.
• Kirtsreesakul V. Chronic sinusitis: Risk factors for extensive disease. Journal of Allergy and Clinical Immunology, 1997.
• Hemilä H et al. Oral vitamin C supplements to prevent and treat acute upper respiratory tract infections. Cochrane Review Protocol, PMC/NIH, 2019.
• Cerullo G et al. Examining the evidence for the use of vitamin C in the prophylaxis and treatment of the common cold. PMC/NIH, 2020.
• Hemilä H, Carr A, Chalker E. Vitamin C May Increase the Recovery Rate of Outpatient Cases of SARS-CoV-2 Infection by 70%. Frontiers in Immunology, PMC/NIH, 2021.
• Zinc Supplementation Reduces Common Cold Duration among Healthy Adults: A Systematic Review. PMC/NIH, 2020.
• Hemilä H, Chalker E. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: systematic review and meta-analysis. PubMed, 2021.
• Ghaheri M et al. Therapeutic Effects of Vitamins and Nutritional Supplements on Sinusitis: A Narrative Review. PMC/NIH, 2024.
• Alharthi et al. The Correlation Between Vitamin D Deficiency and Chronic Rhinosinusitis: A Systematic Review. Cureus, PMC/NIH, 2024.
• Meta-analysis: Association between serum vitamin D and chronic rhinosinusitis. PMC/NIH, 2022.
• Serum 25-Hydroxy Vitamin D in Chronic Rhinosinusitis with and Without Nasal Polyposis: A Case-Control Study. PMC/NIH, 2019.
• Mantri S et al. Association of Vitamin D Status and Acute Rhinosinusitis: Results From NHANES 2001–2006. PMC/NIH, 2015.
• Vitamin D deficiency is associated with increased human sinonasal fibroblast proliferation in chronic rhinosinusitis with nasal polyps. PMC/NIH, 2016.
• Correlation of Serum Vitamin D Levels with Chronic Rhinosinusitis Disease Severity. PMC/NIH, 2019.
• Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial (VITAL). PMC/NIH, 2024.
• The role of oral vitamin D3 supplementation in the treatment of Chronic Rhinosinusitis in adults with Vitamin D deficiency. PMC/NIH, 2020.
• Pavan R et al. Potential role of bromelain in clinical and therapeutic applications. PMC/NIH, 2016.
• Varilla C et al. Bromelain a Potential Bioactive Compound: A Comprehensive Overview from a Pharmacological Perspective. PMC/NIH, 2021.
• Current Uses of Bromelain in Children: A Narrative Review. PMC/NIH, 2024.
• Büttner L et al. Efficacy and tolerability of bromelain in patients with chronic rhinosinusitis — a pilot study. B-ENT, PubMed, 2013.
• Sinus Irrigation with N-Acetylcysteine after Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A Preliminary Report of a Single-Blind Randomized Controlled Trial. PMC/NIH, 2024.
• Macchi A et al. Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy. PubMed, 2012.
• New approach to treatment of polypous rhinosinusitis — NAC in polypous rhinosinusitis outcomes. PubMed, 2020.
• Timmer A et al. Pelargonium sidoides (Umckaloabo) for treating acute respiratory tract infections. Cochrane Library, 2013 (updated summary 2025).
• Timmer A et al. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev, 2008.
• Kolodziej H et al. Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs® 7630) in the Context of Health Promotion. PMC/NIH, 2014.
• Chong LY et al. Saline irrigation for chronic rhinosinusitis. Cochrane Library, 2016 (summary updated 2025).
• Chong LY et al. Saline irrigation for chronic rhinosinusitis. PMC/NIH, 2016 (Cochrane review full text).
• Saline nasal irrigation for acute sinusitis (SNIFS II): a randomised controlled pilot trial with nested process evaluation. BJGP Open, 2025.
• Pelargonium sidoides — Overview and clinical trial data. ScienceDirect Topics.
• Comparative effectiveness of oral nutritional supplements in preventing respiratory tract infections among adults: systematic review and network meta-analysis. ScienceDirect, 2025.